{"id":937629,"date":"2026-02-17T17:08:59","date_gmt":"2026-02-17T22:08:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/"},"modified":"2026-02-17T17:08:59","modified_gmt":"2026-02-17T22:08:59","slug":"summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/","title":{"rendered":"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026<\/b><\/p>\n<p class=\"bwalignc\"><i>Conference Call to be Held at 4:30pm ET<\/i><\/p>\n<p>MIAMI&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSummit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit,\u201d \u201cwe,\u201d or the \u201cCompany\u201d) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes.<\/p>\n<p>\nSummit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.smmttx.com%2F&amp;esheet=54427567&amp;newsitemid=20260217315211&amp;lan=en-US&amp;anchor=www.smmttx.com&amp;index=1&amp;md5=84e378f8e06bebf60b691ba009499402\">www.smmttx.com<\/a>. An archived edition of the session will be available on our website.<\/p>\n<p><b>About Summit Therapeutics<\/b><\/p>\n<p>\nSummit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.<\/p>\n<p>\nSummit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol &#8220;SMMT&#8221;). We are headquartered in Miami, Florida, and we have additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.smmttx.com&amp;esheet=54427567&amp;newsitemid=20260217315211&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.smmttx.com&amp;index=2&amp;md5=c83db3f0690df470952dae2034589f3b\">https:\/\/www.smmttx.com<\/a> and follow us on X <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSMMT_TX&amp;esheet=54427567&amp;newsitemid=20260217315211&amp;lan=en-US&amp;anchor=%40SMMT_TX&amp;index=3&amp;md5=9c62779a4719ef6a77b6dcd7051081b2\">@SMMT_TX<\/a>.<\/p>\n<p><b>Summit Forward-looking Statements<\/b><\/p>\n<p>\nAny statements in this press release about the Company\u2019s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company\u2019s product candidates, entry into and actions related to the Company\u2019s partnership with Akeso Inc., the intended use of the net proceeds from the private placements, the Company&#8217;s anticipated spending and cash runway, the therapeutic potential of the Company\u2019s product candidates, the potential commercialization of the Company\u2019s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (\u201cATM Program\u201d), the expected proceeds and uses thereof, the Company\u2019s estimates regarding stock-based compensation, and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company\u2019s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company\u2019s pipeline of drug candidates, including without limitation, through potential acquisitions of, and\/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company\u2019s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the &#8220;Risk Factors&#8221; and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a \u201cpositive study\u201d as a clinical study that with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company\u2019s views only as of the date of this release and should not be relied upon as representing the Company\u2019s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.<\/p>\n<p class=\"bwalignc\">\nSummit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc. and\/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260217315211\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260217315211\/en\/<\/a><\/span><\/p>\n<p><b>Contact Summit Investor Relations:<br \/>\n<\/b><br \/>Dave Gancarz<br \/>\n<br \/>Chief Business &amp; Strategy Officer<\/p>\n<p>\nNathan LiaBraaten<br \/>\n<br \/>Senior Director, Investor Relations<\/p>\n<p><a rel=\"nofollow\" href=\"mailto:investors@smmttx.com\">investors@smmttx.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"mailto:media@smmttx.com\">media@smmttx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Florida United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260217315211\/en\/2208782\/3\/2024-Summit-logo-RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 Conference Call to be Held at 4:30pm ET MIAMI&#8211;(BUSINESS WIRE)&#8211; Summit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit,\u201d \u201cwe,\u201d or the \u201cCompany\u201d) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 Conference Call to be Held at 4:30pm ET MIAMI&#8211;(BUSINESS WIRE)&#8211; Summit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit,\u201d \u201cwe,\u201d or the \u201cCompany\u201d) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on &hellip; Continue reading &quot;Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-17T22:08:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026\",\"datePublished\":\"2026-02-17T22:08:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/\"},\"wordCount\":882,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/\",\"name\":\"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-02-17T22:08:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/","og_locale":"en_US","og_type":"article","og_title":"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 - Market Newsdesk","og_description":"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 Conference Call to be Held at 4:30pm ET MIAMI&#8211;(BUSINESS WIRE)&#8211; Summit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit,\u201d \u201cwe,\u201d or the \u201cCompany\u201d) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on &hellip; Continue reading \"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-17T22:08:59+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026","datePublished":"2026-02-17T22:08:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/"},"wordCount":882,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/","name":"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-02-17T22:08:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217315211r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-operational-progress-call-on-february-23-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results &amp; Operational Progress Call on February 23, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}